Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Bevacizumab and Erlotinib in High-Risk Prostate Cancer
NCT00203424Phase 2Completed
- Sponsor
- TRIO
- Start
- Jan 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in prostate cancer (PCa), sponsored by TRIO. Primary endpoint: Time to Tumor Recurrence at 3 years. Started Jan 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00203424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203424.